Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholesterol Metabolism Clear all
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Phase 1 Interventional

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

NCT04532047
View directory record Official record
Conditions
MPS I, MPS II, MPS IVA, MPS VI, Mps VII, Gaucher Disease, Type 2, Gaucher Disease, Type 3, Pompe Disease Infantile-Onset, Wolman Disease
Interventions
Aldurazyme (laronidase)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Nurse Telephone Management of Cholesterol in Diabetes

NCT00950963
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Phone Counseling, Standard Clinical Care
Behavioral · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
17 Years and older
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional

The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors

NCT01235832
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Avocado Diet, Lower-Fat Diet, Moderate Fat Diet
Other
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Gene x Behavior Interaction in the Look AHEAD Study

NCT01270763
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Intensive lifestyle intervention, Diabetes support and education
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
45 Years to 74 Years
Enrollment
4,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00280995
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jun 10, 2026, 2:27 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Liver Adiposity Effects on Pediatric Statin

NCT04903223
View directory record Official record
Conditions
Cholesterol; Lipidosis
Interventions
Rosuvastatin 10mg
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

NCT05333107
View directory record Official record
Conditions
Healthy Volunteers; High Cholesterol
Interventions
NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Cypress, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study

NCT02270164
View directory record Official record
Conditions
Lipid Metabolism Disorders
Interventions
Artichoke Leaf Extract, Placebo
Dietary Supplement · Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jun 10, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional

A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

NCT00494663
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DIO-902, DIO-902 placebo
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2008 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?

NCT03368066
View directory record Official record
Conditions
Adrenal Insufficiency, Cirrhosis, Spur Cell Anemia, Lecithin Acyltransferase Deficiency
Interventions
Cosyntropin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 110 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mediterranean Full-Fat Dairy Study

NCT02781675
View directory record Official record
Conditions
Cardiovascular Disease, Dyslipidemia, Inflammation
Interventions
Dietary Intervention
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Increasing Medication Adherence Through Physician Incentives and Messaging

NCT01603329
View directory record Official record
Conditions
Medication Adherence
Interventions
Increasing Medication Adherence through Physician Incentives and Messaging
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Jun 10, 2026, 2:27 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Elevated Cholesterol

NCT04148339
View directory record Official record
Conditions
Cholesterol, Elevated, Elevated Cholesterol
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430
View directory record Official record
Conditions
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

NCT06640972
View directory record Official record
Conditions
Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
Interventions
RDX-002, Placebo
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

NCT00346697
View directory record Official record
Conditions
HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions
Omega-3 fatty acid administration, Placebo
Drug
Lead sponsor
Brown, Todd, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jun 10, 2026, 2:27 PM EDT
Completed No phase listed Observational

Evaluation of Lipoproteins

NCT00001168
View directory record Official record
Conditions
Evaluation of Plasma Lipoproteins
Interventions
Balanced diet
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1979
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

NCT02867813
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
5,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825
View directory record Official record
Conditions
Hypercholesterolemia, Heterozygous Familial
Interventions
mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
20
States / cities
Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jun 10, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

NCT00129792
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions
Dietary supplement for weight loss, Education and counseling for weight loss
Drug · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jun 10, 2026, 2:27 PM EDT